We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
+10.95%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$950M
AUM Growth
+$325M
(+52%)
Cap. Flow
+$425M
Cap. Flow
% of AUM
44.74%
Top 10 Holdings %
Top 10 Hldgs %
62.17%
Holding
40
New
10
Increased
8
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$187M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$84.3M |
| 3 |
Travere Therapeutics
TVTX
|
+$37M |
| 4 |
HLVX
HilleVax
HLVX
|
+$28.7M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GH Research
GHRS
|
+$8.93M |
| 2 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$7.18M |
| 3 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$5.65M |
| 4 |
Black Diamond Therapeutics
BDTX
|
+$1.79M |
| 5 |
Avalo Therapeutics
AVTX
|
+$444K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apogee Therapeutics
APGE
$10.1B
| $181M | 19.04% |
+8,493,321
| New | +$187M |
|
|
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $89.2M | 9.39% |
+4,016,847
| New | +$84.3M |
|
3
Viridian Therapeutics
VRDN
$2.09B
| $47.3M | 4.98% |
3,082,622
| – | – |
|
4
Cogent Biosciences
COGT
$6.65B
| $45.7M | 4.81% |
4,684,167
+35
| +0% | +$415 |
|
|
5
Taysha Gene Therapies
TSHA
$1.68B
| $45.6M | 4.81% |
+14,444,444
| New | +$27M |
|
|
MRUS
6
DELISTED
Merus
MRUS
| $40.7M | 4.28% |
1,726,214
| – | – |
|
7
Enliven Therapeutics
ELVN
$3.92B
| $40.4M | 4.25% |
2,954,902
+724,775
| +32% | +$12.2M |
|
8
4D Molecular Therapeutics
FDMT
$532M
| $38.2M | 4.02% |
3,000,000
| – | – |
|
9
Pharvaris
PHVS
$2.28B
| $32.6M | 3.44% |
1,563,513
+237,313
| +18% | +$4.37M |
|
10
Cabaletta Bio
CABA
$437M
| $30M | 3.16% |
1,973,253
+2
| +0% | +$27 |
|
|
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
| $28.1M | 2.96% |
2,916,667
| – | – |
|
|
12
GH Research
GHRS
$1.93B
| $27.6M | 2.9% |
2,744,125
-773,000
| -22% | -$8.93M |
|
|
HLVX
13
DELISTED
HilleVax
HLVX
| $27.4M | 2.88% |
+2,037,313
| New | +$28.7M |
|
14
Savara
SVRA
$1.12B
| $27.2M | 2.86% |
7,184,865
+833,334
| +13% | +$2.97M |
|
15
Rhythm Pharmaceuticals
RYTM
$6.81B
| $25M | 2.63% |
1,090,000
| – | – |
|
|
AMAM
16
DELISTED
Ambrx Biopharma Inc
AMAM
| $23.8M | 2.51% |
2,070,000
-414,960
| -17% | -$5.65M |
|
|
17
Travere Therapeutics
TVTX
$5.2B
| $23.5M | 2.47% |
+2,623,677
| New | +$37M |
|
18
Dyne Therapeutics
DYN
$4.7B
| $19.5M | 2.05% |
2,173,913
| – | – |
|
19
Celcuity
CELC
$4.21B
| $19.2M | 2.03% |
2,105,386
| – | – |
|
|
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
| $15.6M | 1.64% |
3,092,273
+119,404
| +4% | +$758K |
|
|
MRSN
21
DELISTED
Mersana Therapeutics
MRSN
| $14.4M | 1.51% |
+453,120
| New | +$21.5M |
|
|
APLT
22
DELISTED
Applied Therapeutics
APLT
| $14.1M | 1.48% |
5,658,034
| – | – |
|
23
Oric Pharmaceuticals
ORIC
$1.15B
| $13M | 1.36% |
2,142,856
| – | – |
|
24
Dianthus Therapeutics
DNTH
$5.84B
| $12.7M | 1.34% |
+927,706
| New | +$11.7M |
|
|
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
| $9.86M | 1.04% |
657,330
+268,705
| +69% | +$4.82M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q3 2023 Portfolio in Review
As of Q3 2023, VR Adviser held 40 positions worth $950M, up 52% from $625M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
VR Adviser deployed $425M of net new capital in Q3 2023, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was Apogee Therapeutics: 8,493,321 shares worth $181M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was GH Research, an estimated $8.93M trimmed.
- VR Adviser's largest Q3 2023 buy was Apogee Therapeutics: 8,493,321 shares worth $181M.
- VR Adviser added most to Enliven Therapeutics in Q3 2023, an estimated $12.2M increase.
- VR Adviser's biggest Q3 2023 reduction was GH Research, cutting an estimated $8.93M.
- VR Adviser fully exited Theseus Pharmaceuticals, Inc. Common Stock in Q3 2023, selling an estimated $7.18M.
- VR Adviser's ten largest holdings make up 62% of its $950M portfolio in Q3 2023.
- VR Adviser opened 10 new positions and closed 3 in Q3 2023.
- VR Adviser's portfolio value rose 52% quarter-over-quarter to $950M.
Based on VR Adviser's 13F filing for Q3 2023, filed 14 Nov 2023.